ARS Wealth Advisors Group LLC Makes New $960,000 Investment in Abbott Laboratories $ABT

Key Points

• ARS Wealth Advisors Group LLC acquired a new position in Abbott Laboratories, purchasing 7,056 shares valued at approximately $960,000 during the second quarter.
• Several large investors increased their stakes in Abbott Laboratories, with significant boosts from Mogy Joel R Investment Counsel Inc. and Exchange Traded Concepts LLC, reflecting growing institutional interest as they own over 75% of the company's stock.
• Abbott Laboratories reported earnings of $1.26 per share for the previous quarter, aligning with analysts' estimates, and projected FY 2025 EPS guidance of 5.100-5.200.

ARS Wealth Advisors Group LLC purchased a new stake in Abbott Laboratories (NYSE:ABT - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 7,056 shares of the healthcare product maker's stock, valued at approximately $960,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Hughes Financial Services LLC bought a new position in Abbott Laboratories in the first quarter valued at approximately $27,000. Abound Financial LLC bought a new stake in shares of Abbott Laboratories during the first quarter worth $28,000. Elequin Capital LP bought a new stake in shares of Abbott Laboratories during the first quarter worth $30,000. Wormser Freres Gestion bought a new stake in shares of Abbott Laboratories during the fourth quarter worth $32,000. Finally, JCIC Asset Management Inc. bought a new stake in shares of Abbott Laboratories during the first quarter worth $32,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.46% of the company's stock.

Abbott Laboratories Stock Up 1.2%

Shares of NYSE ABT traded up $1.65 during trading on Friday, hitting $136.22. 11,531,874 shares of the company traded hands, compared to its average volume of 4,828,819. The business's fifty day moving average is $130.47 and its 200 day moving average is $131.19. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The firm has a market capitalization of $237.09 billion, a price-to-earnings ratio of 17.07, a P/E/G ratio of 2.55 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the prior year, the business earned $1.14 earnings per share. The business's quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio is presently 29.57%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Morgan Stanley boosted their price objective on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. Jefferies Financial Group raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. Leerink Partners assumed coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They issued a "market perform" rating and a $143.00 price objective on the stock. Finally, Royal Bank Of Canada boosted their price objective on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, Abbott Laboratories has a consensus rating of "Moderate Buy" and an average price target of $145.22.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.